Trefoil peptides

Gut

Volumn 44, Issue 6, 1999, Pages 890-895

  Wong, W M ^b   Poulsom, R ^b   Wright, N A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTESTINAL TREFOIL FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN; TREFOIL PEPTIDE;

DRUG MECHANISM; ENTERITIS; GASTROINTESTINAL TRACT; HUMAN; INTESTINE MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVIEW; TUMOR GROWTH; ULCER;

EID: 0001588530     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.44.6.890     Document Type: Review

References (88)

1. Masiakowski P, Breathnach R, Bloch J, et al. Cloning of cDNA sequences of hormone regulated genes from the MCF-7 human breast cancer cell line. Nucl Acids Res 1982;10:7895-903.
2. Jorgensen KD, Diamont B, Jorgensen KH, et al. Pancreatic spasmolytic polypeptide (PSP). III. Pharmacology of a new porcine pancreatic polypeptide with spasmolytic and gastric acid inhibiting effects. Regul Pept 1982;3:231-43.
3. Jorgensen KH, Thim L, Jacobsen HE. Pancreatic spasmolytic polypeptide (PSP). I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas. Regul Pept 1982;3:207-19.
4. Thim L, Jorgensen KH, Jorgensen KD. Pancreatic spasmolytic polypeptide (PSP). II. Radioimmunological determination of PSP in porcine tissues, plasma and pancreatic juice. Regul Pept 1982;3:221-30.
5. Baker ME. Oestrogen-induced pS2 protein is similar to pancreatic spasmolytic polypeptide and the kringle domain. Biochem J 1988;253:307-9.
6. Thim L. A surprising sequence homology. Biochem J 1988;253:309.
7. Thim L. A new family of growth factor-like peptides: 'trefoil' disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP) and frog skin peptides (spasmolysins). FEBS Lett 1989;250:85-90.
8. Hoffman W. A new repetitive protein from Xenopus laevis skin highly homologous to pancreatic spasmolytic polypeptide. J Biol Chem 1988;263:7686-90.
9. Suemori S, Lynch-Devaney K, Podolsky DK. Identification and characterization of rat intestinal trefoil factor: tissue- and cell-specific member of the trefoil protein family. Proc Natl Acad Sci USA 1991;88:11017-21.
10. Hauser F, Poulsom R, Chinery R, et al. hPLB, a human P-domain peptide hologous with rat intestinal trefoil factor, is expressed in the ulcer-associated cell lineage and in the uterus. Proc Natl Acad Sci USA 1993;90:6961-5.
11. Podolsky DK, Lynch-Devaney K, Stow JL, et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993;268:6694-702.
12. Podolsky DK, Lynch-Devaney K, Stow JL, et al. Identification of human intestinal trefoil factor. Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993;268:12230.
13. Gmachl M, Berger H, Thalhammer J, et al. Dermal glands of Xenopus laevis contain a polypeptide with a highly repetitive amino acid sequence. FEBS Lett 1990;260:145-8.
14. Hauser F, Hoffman W. xP1 and xP4. P-domain peptides expressed in Xenopus laevis stomach mucosa. J Biol Chem 1991;266:21306-9.
15. Hauser F, Roeben W, Hoffman W. xP2, a new member of the P-domain peptide family of potential growth factors, is synthesized in Xenopus laevis skin. J Biol Chem 1992;267:14451-5.
16. Hoffman W, Hauser F. The P-domain or trefoil motif: a role in renewal and pathology of mucous epithelia? Trends Biochem Sci 1993;18:239-43.
17. Moisan JP, Mattei MG, Mandel JL. Chromosome localization and polymorphism of an oestrogen-inducible gene specifically expressed in some breast cancers. Hum Genet 1988;79:168-71.
18. Prud'homme JF, Fridlansky F, Le Cunff M, et al. Cloning of a gene expressed in human breast cancer and regulated by estrogen in MCF-7 cells. DNA 1985;4:11-21.
19. Tomasetto C, Rockel N, Mattei MG, et al. The gene encoding the human spasmolytic protein (SML1/hSP) is in 21q22.3, physically linked to the homologous breast cancer marker gene, BCEI/pS2. Genomics 1992;13:1328-30.
20. Chinery R, Williamson J, Poulsom R. The gene encoding human intestinal trefoil factor (TFF3) is located on chromosome 21q22.3 clustered with other members of the trefoil peptide family. Genomics 1996;32:281-4.
21. Schmitt H, Wundrack I, Beck S, et al. A third P-domain peptide gene (TFF3), human intestinal trefoil factor, maps to 21q22.3. Cytogenet Cell Genet 1996;72:299-302.
22. Wright NA, Hoffmann W, Otto WR, et al. Rolling in the clover: trefoil factor family (TFF)-domain peptides, cell migration and cancer. FEBS Lett 1997;408:121-3.
23. Tomasetto C, Rio MC, Gautier C, et al. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J 1990;9:407-14.
24. Hanby AM, Poulsom R, Singh S, et al. Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic polypeptide and pS2 in the stomach. Gastroenterology 1993;105:1110-16.
25. Hanby AM, Poulsom R, Playford RJ, et al. The mucous neck cell in the human gastric corpus: A distinctive, functional cell lineage. J Pathol 1999;187:331-7.
26. Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature 1990;343:82-5.
27. May FEB, Westley BR. Cloning of estrogen-regulated messenger RNA sequences from human breast cancer cells. Cancer Res 1986;46:6034-40.
28. Henry JA, Piggott NH, Mallick UK, et al. pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br J Cancer 1991;63:615-22.
29. Bonkhoff H, Stein U, Welter C, et al. Differential expression of the pS2 protein in the human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995;26:824-8.
30. Henry JA, Nicholson S, Hennessy C, et al. Expression of the estrogen-regulated pNR-2 mRNA levels and response to tamoxifen therapy. Br J Cancer 1989;61:32-8.
31. Cappelletti V, Coradini D, Scanziani E, et al. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur J Cancer 1992;28:1315-18.
32. Foekens JA, Rio MC, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 1990;50:3832-7.
33. Pallud C, Le Dousal V, Pichon MF, et al. Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours. Histopathology 1993;23:249-56.
34. Rio MC, Bellocq JP, Gairard B, et al. Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2. Proc Natl Acad Sci USA 1987;84:9243-7.
35. Skilton RA, Luqmani YA, McClelland RA, et al. Characterisation of a messenger RNA selectively expressed in human breast cancer. Br J Cancer 1989;60:168-75.
36. Poulsom R, Hanby AM, Lalani EN, et al. Intestinal trefoil factor (TFF3) and pS2 (TFF1), but not spasmolytic polypeptide (TFF2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 1997;183:30-8.
37. Machado JC, Carneiro F, Blin N, et al. Pattern of pS2 protein expression in premalignant and malignant lesions of gastric mucosa. Eur J Cancer Prev 1996;5:169-79.
38. Henry JA, Bennett MK, Piggott NH, et al. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 1991;64:677-82.
39. Luqmani Y, Bennett C, Paterson I, et al. Expression of the pS2 gene in normal, benign, and neoplastic human stomach. Int J Cancer 1989;44:806-12.
40. Muller W, Borchard F. pS2 protein in gastric carcinoma and normal gastric mucosa: association with clinicopathological parameters and patient survival. J Pathol 1993;171:263-9.
41. Machado JC, Carneiro F, Ribeiro P, et al. pS2 protein expression in gastric carcinoma. An immunohistichemical and immuoradiometric study. Eur J Cancer 1996;32:1585-90.
42. Theisinger B, Welter C, Seitz G, et al. Expression of the breast cancer associated gene pS2 and the pancreatic spasmolytic polypeptide gene (hSP) in diffuse type of stomach carcinoma. Eur J Cancer 1991;27:770-3.
43. Taupin D, Ooi K, Yeomans N, et al. Conserved expression of intestinal trefoil factor in the human colonic adenoma-adenocarcinoma sequence. Lab Invest 1996;75:25-32.
44. Higashiyama M, Doi O, Kodama K, et al. Prognostic significance of pS2 protein expression in pulmonary adenocarcinoma. Eur J Cancer 1994;30:792-7.
45. Higashiyama M, Doi O, Kodama K, et al. Estimation of serum pS2 protein in patients with lung adenocarcinoma. Anticancer Res 1996;16:2351-6.
46. Welter C, Theisinger B, Seitz G, et al. Association of the human spasmolytic polypeptide and an oestrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 1992;66:187-92.
47. Collier JD, Bennett MK, Bassendine MF, et al. Immunolocalisation of pS2, a putative growth factor, in pancreatic carcinoma. J Gastroenterol Hepatol 1995;10:296-300.
48. Wang DG, Liu WH, Lundy FT, et al. TFF1 gene expression in human medullary thyroid carcinoma. J Pathol 1998;184:408-13.
49. Hanby AM, McKee P, Jeffery M, et al. Primary mucinous carcinomas of the skin express TFF1, TFF3, estrogen receptor, and progesterone receptors. Am J Surg Pathol 1998;22:1125-31.
50. Wolfe HJ, Melvin KEW, Cervi-Skinner SJ, et al. C-cell hyperplasia preceding medullary thyroid carcinoma. N Engl J Med 1973;289:437-41.
51. Wright NA, Poulsom R, Stamp GWH, et al. Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993;104:12-20.
52. Hanby AM, Jankowski JAZ, Elia G, et al. Expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in Barrett's metaplasia and the native oesophageal epithelium: delineation of epithelial phenotype. J Pathol 1994;173:213-19.
53. Levi S, Goodlad RA, Lee CY, et al. Effects of epithelial proliferation and differentiation on ulcer healing. Eur J Gastroenterol Hepatol 1993;5(suppl 3):S39-43.
54. Alison MR, Chinery R, Poulsom R, et al. Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol 1995;175:405-14.
55. Hanby AM, Poulsom R, Elia G, et al. The expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in 'gastric metaplasia' of the proximal duodenum: implications for the nature of 'gastric metaplasia'. J Pathol 1993;169:355-60.
56. Wright NA, Poulsom R, Stamp GWH, et al. Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol 1990;162:279-84.
57. Rio MC, Chenard MP, Wolf C, et al. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991;100:375-9.
58. Hanby AM, Wright NA. The ulcer-associated cell lineage: the gastrointestinal repair kit? J Pathol 1993;171:3-4.
59. Williams R, Stamp GW, Gilbert C, et al. pS2 transfection of murine adenocarcinoma cell line 410.4 enhances dispersed growth pattern in a 3D collagen gel. J Cell Sci 1996;109:63-71.
60. Dignass A, Lynch-Devaney K, Kindon H, et al. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest 1994;94:376-83.
61. Playford RJ, Marchback T, Chinery R, et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 1995;108:108-116.
62. Hauser F, Hoffmann W. P-domains as shuffled cysteine-rich modules in integumentary mucin C.1 (FIM-C.1) from Xenopus laevis. Polydispersity and genetic polymorphism. J Biol Chem 1992;267:24620-4.
63. Sands BE, Ogata H, Lynch-Devaney K, et al. Molecular cloning of the rat intestinal trefoil factor gene. Characterization of an intestinal goblet cell-associated promoter. J Biol Chem 1995;270:9353-61.
64. Ogata H, Inoue N, Podolsky DK. Identification of a goblet cell-specific enhancer element in the rat intestinal trefoil factor gene promoter bound by a goblet cell nuclear protein. J Biol Chem 1998;273:3060-7.
65. Tanaka S, Podolsky DK, Engel E, et al. Human spasmolytic polypeptide decreases proton permeation through gastric mucus in-vivo and in-vitro. Am J Physiol 1997;35:G1473-80.
66. Sands BE, Podolsky DK. The trefoil peptide family. Annu Rev Physiol 1996;58:253-73.
67. Otto WR, Rao J, Cox HM, et al. Effects of pancreatic spasmolytic polypeptide (PSP) on epithelial cell function. Eur J Biochem 1996;235:64-72.
68. Lebefvre O, Chenard MP, Masson R, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996;274:259-62.
69. Babyatsky MW, DeBeaumont M, Thim L, et al. Oral trefoil peptides protect against ethanol and indomethacin induced gastric injury in rats. Gastroenterology 1996;110:489-97.
70. Playford RJ. Peptides and gastrointestinal mucosal integrity. Gut 1995;37:595-97.
71. Mashimo H, Wu DC, Podolsky DK. Impaired defence of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996;274:262-5.
72. Hanby AM, Pera M, Filipe I, et al. Duodenal content reflux esophagitis in the rat: an animal model for the ulcer-associated cell lineage (UACL)? Am J Pathol 1997;151:1819-24.
73. Chinery R, Cox HM. Modulation of epidermal growth factor effects on epithelial ion transport by intestinal trefoil factor. Br J Pharmacol 1995;115:77-80.
74. Chinery R, Cox HM. Immunoprecipitation and characterization of a binding protein specific for the peptide, intestinal trefoil factor. Peptides 1995;16:749-55.
75. Frandsen EK, Jorgensen KH, Thim L. Receptor binding of pancreatic spasmolytic polypeptide (PSP) in rat intestinal mucosal cell membranes inhibits the adenylate cyclase activity. Regul Pept 1986;16:291-7.
76. Carr M. H NMR-based determination of the secondary structure of porcine pancreatic spasmolytic polypeptide: one of a family of 'trefoil' motif containing cell growth factors. Biochemistry 1992;31:1998-2004.
77. Gajhede M, Patersen TN, Henriksen A, et al. Pancreatic spasmolytic polypeptide: first three-dimensional structure of a member of the mammalian trefoil family of peptides. Structure 1993;1:253-62.
78. De A, Brown DG, Gorman MA, et al. Crystal structure of a disulphide-linked 'trefoil' motif found in a large family of putative growth factors. Proc Natl Acad Sci USA 1994;91:1084-8.
79. Chinery R, Bates PA, De A, et al. Characterization of the single copy trefoil peptides intestinal trefoil factor and pS2 and their ability to form covalent dimers. FEBS Lett 1995;357:50-4.
80. Chadwick MP, May FEB, Westley BR. Homodimerisation and hetero-oligodimerisation of the single-domain trefoil protein pNR-2/pS2 through cysteine 58. Biochem J 1997;327:117-23.
81. Thim L, Wöldike HF, Nielsen PF, et al. Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 1995;34:4757-64.
82. Marchbank T, Westley RR, May FEB, et al. Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. J Pathol 1998;185:153-8.
83. Servent D, Winckler-Dietrich V, Hu HY, et al. Only snake curaremimetic toxins with a fifth disulphide bond have a high affinity for the neuronal α7 nicotinic receptor. J Biol Chem 1997;272:24279-86.
84. Marcel M, Boterberg T, Noe V, et al. E-cadherin/catenin/cytoskeleton complex: a regulator of cancer invasion. J Cell Physiol 1997;173:271-4.
85. Liu D, El-Hariry, Karayiannakis AJ, et al. Phosphorylation of β-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 1997;77:557-63.
86. Efstathiou JA, Noda M, Rowan A, et al. Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci USA 1998;95:3122-7.
87. Kanai M, Mullen C, Podolsky DK. Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells. Proc Natl Acad Sci USA 1998;95:178-82.
88. Chinery R, Playford RJ. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci 1995;88:401-3.